

25 Aug 2017 | **Analysis**

SNAPSHOT: Inhalation Drug Delivery Devices Growing Slowly But Surely

by


The rise in respiratory problems such as asthma and chronic obstructive pulmonary disorder will buoy growth in the \$11.7bn inhalation drug delivery device market. While global sales increase of these devices will be modest, some geographic regions will see faster pace growth than others, according to a [report](#) by Meddevicetracker.

Inhalation Drug Delivery Devices Market Inflates Slowly But Surely

Sales of inhalation drug delivery devices (DDD) will continue to grow but at a modest rate. The rising prevalence of asthma and chronic obstructive pulmonary disease across the world, especially the US, is one of the factors that will drive sales of these devices to reach \$12.4bn in 2021. New forms of drug therapies will also help expand the market.

103.9 m

No. of patients with asthma and COPD that would use inhalation DDDs.



\$11.7bn


2016

GLOBAL
SALES OF
INHALATION
DDDS


\$12.4bn

2021

SALES BREAK-
DOWN BY
INDICATION



2016



2021

THE INHALATION DDD
MARKET IS
DOMINATED BY 3 PLAYERS



91%

TOTAL MARKET
SHARE HELD BY THE
TOP 3 PLAYERS



Triple combination therapies are the latest innovation in respiratory disease treatment. They combine inhaled corticosteroids, long-acting muscarinic antagonists and long-acting beta 2 agonist medications, all delivered via one device.

Source: Meddevicetracker's Inhalation Drug Delivery Device Market Report